Literature DB >> 3033269

Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

G R Nemerow, C Mold, V K Schwend, V Tollefson, N R Cooper.   

Abstract

The major Epstein-Barr virus (EBV) envelope glycoprotein, gp350, was purified from the B95-8 cell line and analyzed for its ability to mediate virus attachment to the isolated EBV/C3d receptor (CR2) of human B lymphocytes. Purified gp350 and EBV, but not cytomegalovirus, exhibited dose-dependent binding to purified CR2 in dot blot immunoassays. Binding was inhibited by certain monoclonal antibodies to CR2 and to gp350. Liposomes bearing incorporated gp350 bound to CR2-positive B-cell lines but not to CR2-negative lines. Liposome binding was also inhibited by the OKB7 anti-CR2 monoclonal antibody. A computer-generated comparison of the deduced gp350 amino acid sequence with that of the human C3d complement fragment revealed two regions of significant primary sequence homology, a finding which suggests that a common region on these two unrelated proteins may be involved in CR2 binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033269      PMCID: PMC254117          DOI: 10.1128/JVI.61.5.1416-1420.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Comparison of enzyme-linked immunosorbent assay (ELISA) technique and complement-fixation test for estimation of cytomegalovirus IgG antibody.

Authors:  J C Booth; G Hannington; T A Aziz; H Stern
Journal:  J Clin Pathol       Date:  1979-02       Impact factor: 3.411

2.  Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.

Authors:  G R Nemerow; M F Siaw; N R Cooper
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

5.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells.

Authors:  A Wells; N Koide; G Klein
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

7.  An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200).

Authors:  M Hummel; D Thorley-Lawson; E Kieff
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

8.  Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.

Authors:  L F Qualtiere; R Chase; G R Pearson
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

9.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

10.  Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement.

Authors:  G R Nemerow; N R Cooper
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

View more
  127 in total

1.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Molecular mimicry as a mechanism for virus-induced autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

4.  Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Authors:  Susan M Turk; Ru Jiang; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42.

Authors:  R Jiang; R S Scott; L M Hutt-Fletcher
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 6.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

7.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

9.  Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.

Authors:  R S Haddad; L M Hutt-Fletcher
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding.

Authors:  Andrea E Prota; David R Sage; Thilo Stehle; Joyce D Fingeroth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.